Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel

Bibliography

• Neligan A, Hauser WA, Sander JW. The epidemiology of the epilepsies. Handb Clin Neurol 2012;107:113-33
   PubMedGoogle Scholar
• Tolman JA, Faulkner MA. Treatment options for refractory and difficult to treat seizures: focus on vigabatrin. Ther Clin Risk Manag 2011;7:367-75
   PubMed Web of Science ®Google Scholar
• Faught E. Ezogabine: a new angle on potassium gates. Epilepsy Curr 2011;11:75-8
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817-24
   PubMed Web of Science ®Google Scholar
• Biervert C, Schroeder BC, Kubisch C, et al. A potassium channel mutation in neonatal human epilepsy. Science 1998;279:403-6
   PubMed Web of Science ®Google Scholar
• Charlier C, Singh NA, Ryan SG, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family [abstract]. Nat Genet 1998;18:53
   PubMed Web of Science ®Google Scholar
• Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns [abstract]. Nat Genet 1998;18:25-9
   PubMed Web of Science ®Google Scholar
• Gao Z, Zhang T, Wu M, et al. Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions. J Biol Chem 2010;285:28322-32
   PubMed Web of Science ®Google Scholar
• Porter RJ, Partiot A, Sachdeo R, et al. Randomized, multicenter, dose-ranging trial of retigabine for partial onset seizures. Neurology 2007;68:1197-204
   PubMed Web of Science ®Google Scholar
• French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011;76:1555-63
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Brodie MJ, Leroy R, et al. Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: interim results from two ongoing open-label studies. Epilepsy Res 2012;102:117-21
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Ezogabine (Potiga) package insert. Research Triangle Park, NC: 2011
   Google Scholar
• Amabile CM, Vasudevan A. Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures. Pharmacotherapy 2013;33:187-94
   PubMed Web of Science ®Google Scholar
• Mohanraj R, Brodie MJ. Measuring the efficacy of antiepileptic drugs. Seizure 2003;12:413-43
   PubMed Web of Science ®Google Scholar
• Anderson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004;84:935-86
   PubMed Web of Science ®Google Scholar
• Chen M, kellett WF, Petkov GV. Voltage-gated K(+) channels sensitive to stromatoxin-1 regulate myogenic and neurogenic contractions of rat urinary bladder smooth muscle. Am J Physiol Regul Inter Comp Physiol 2010;299:R177-84
   Google Scholar
• Brickel N, Gandhi P, VanLandingham K, et al. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels. Epilepsia 2012;53:606-12
   PubMed Web of Science ®Google Scholar
• Rode F, Svalo J, Sheykhzade M, et al. Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder. Eur J Pharmacol 2010;638:121-7
   PubMed Web of Science ®Google Scholar
• Streng T, Chrisoph T, Andersson KE. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J urol 2004;172:2054-8
   PubMed Web of Science ®Google Scholar
• Brickel N, Hammond J, DeRossett S. Pharmacological effects of retigabine on bladder function: results from phase 2/3 studies [abstract]. American Epilepsy Society Annual Meeting; 2010. Available from: http://www.aesnet.org/go/publications/aes-abstracts/abstract-search?mode=display&sy=2010&sb=all&startrow=941&id=12472 [Last accessed 26 April 2013]
   Google Scholar
• FDA Drug Safety Communication: anti-seizure drug Potiga (ezogabine) linked to retinal abnormalities and blue skin discoloration. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm349538.htm [Last accessed 10 May 2013]
   Google Scholar
• Tompson DJ, van Landingham KE. The effects of retigabine on the pharmacokinetic of concomitantly administered antiepileptic drugs [abstract 187]. 9th Eur Congr Epileptology; 2010
   Google Scholar
• Hermann R, Knebel NG, Niebch G, et al. Pharmacokinetic interaction between lamotrigine and retigabine in healthy subjects. Eur J Clin Pharmacol 2003;58:795-802
   PubMed Web of Science ®Google Scholar
• Weisenbert JLZ, Wong M. Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures. Neuropsychiatr Dis Treat 2011;7:409-14
   PubMedGoogle Scholar
• Ferron GM, Paul J, Richards L, et al. Retigabine does not alter the pharmacokinetics of a low dose oral contraceptive in women [abstract]. Neurology 2001;56(Suppl 3):abstract P.05.052
   Google Scholar
• Ferron GM, Patat A, Parks V, et al. Lack of pharmacokinetic interaction between retigabine and pehnobarbitone at steady-state in healthy subjects. Br J Clin Pharmacol 2003;56:39-45
   PubMed Web of Science ®Google Scholar
• Department of Justice. DEA 21 CFR part 1308. Schedules of controlled substances: placement of ezogabine into schedule V. Available from: http://www.regulations.gov/#!documentDetail;D=DEA-2011-0013-0001 [Last accessed 7 May 2013]
   Google Scholar
• Takagaki G. The dawn of excitatory amino acid research in Japan. The pioneering work by Professor takashi Hayashi. Neurochem Int 1996;29:225-9
   PubMed Web of Science ®Google Scholar
• During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 1993;341:1607-10
   PubMed Web of Science ®Google Scholar
• Le DA, Lipton SA. Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging 2001;18:717-24
   PubMed Web of Science ®Google Scholar
• Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011;11:56-63
   PubMed Web of Science ®Google Scholar
• Plosker GL. Perampanel as adjunctive therapy in patients with partial onset seizures. CNS Drugs 2012;26:1085-96
   PubMed Web of Science ®Google Scholar
• Meldrum BS. Implications for neuroprotective treatments. Prog Brain Res 2002;135:487-95
   PubMedGoogle Scholar
• Frandsen A, Schousboe A. AMPA receptor-mediated neurotoxicity: role of Ca2+ and desensitization. Neurochem Res 2003;28:1495-9
   PubMed Web of Science ®Google Scholar
• Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012;125:8-15
   PubMed Web of Science ®Google Scholar
• Krauss RI, Bar M, Biton V, et al. Perampanel study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012;126:263-9
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79:589-96
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013;54:117-25
   PubMed Web of Science ®Google Scholar
• Krauss GL, Serratosa JM, Villanueva V. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 306. Neurology 2012;78:1408-15
   PubMed Web of Science ®Google Scholar
• Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia 2013;54:126-34
   PubMed Web of Science ®Google Scholar
• Serratosa JM, Villanueva V, Kerling F, et al. Safety and tolerability of perampanel: a review of clinical trial data. Acta Neurol Scand 2013;127(Suppl 197):30-5
   Web of Science ®Google Scholar
• Eisai, Inc. Perampanel (Fycompa) package insert. Woodcliff Lake, NJ: 2012
   Google Scholar